Dynavax Technologies Corp buy marge
Start price
28.06.17
/
50%
€9.11
Target price
04.11.21
€12.00
Performance (%)
93.79%
End price
05.11.21
€17.66
Summary
This prediction ended on 05.11.21 with a price of €17.66. The BUY prediction by marge for Dynavax Technologies Corp saw massive gains of 93.79%. marge has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Dynavax Technologies Corp | 3.249% | 3.249% | 5.724% | 46.528% |
| iShares Core DAX® | 0.476% | -0.039% | 13.342% | 17.330% |
| iShares Nasdaq 100 | 1.290% | 0.504% | 40.099% | 50.534% |
| iShares Nikkei 225® | 1.300% | -2.135% | 19.861% | 4.937% |
| iShares S&P 500 | 0.829% | 0.193% | 29.756% | 43.432% |
Comments by marge for this prediction
In the thread Dynavax Technologies Corp diskutieren
marge stimmt der Buy-Einschätzung von datca zu
marge stimmt am 286.2017 der Buy-Einschätzung von datca mit dem Kursziel 16€ zu.
Überschrift: Dynavax auf gutem Wege mit Hepatitis B-Impfstoff in der Zulassung
The hepatitis B vaccine space is an over $500 million market just in the United States. If approved, I expect the stock to trade up into the mid-teens. Heplisav-B has an Ad Comm Panel on July 28th and a PDUFA date of August 10th.
Kursziel geändert auf 12,0
In the thread Trading Dynavax Technologies Corp
Die von marge gewählte maximale Laufzeit wurde überschritten
Stopped prediction by marge for Dynavax Technologies Corp
Dynavax Technologies Corp
Start price
Target price
Perf. (%)
€9.82
28.09.16
28.09.16
€10.82
28.03.17
28.03.17
-44.44%
28.03.17
28.03.17
